Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Fulcrum Therapeutics Inc.

    NASDAQ: FULC · Real-Time Price · USD
    7.08
    -0.30 (-4.07%)
    At close: Jun 27, 2025, 2:01 PM

    Fulcrum Therapeutics Statistics

    Share Statistics

    Fulcrum Therapeutics has 53.98M shares outstanding. The number of shares has increased by -13.15% in one year.

    Shares Outstanding

    n/a
    		 53.98M

    Shares Change (YoY)

    n/a
    		 -13.15%

    Shares Change (QoQ)

    n/a
    		 0.08%

    Owned by Institutions (%)

    n/a
    		 82.88%

    Shares Floating

    n/a
    		 47.85M

    Failed to Deliver (FTD) Shares

    n/a
    		 31,882

    FTD / Avg. Volume

    n/a
    		 5.7%

    Short Selling Information

    The latest short interest is 5.68M, so 10.53% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.68M

    Short % of Shares Out

    n/a
    		 10.53%

    Short % of Float

    n/a
    		 13.63%

    Short Ratio (days to cover)

    n/a
    		 8.39

    Valuation Ratios

    The PE ratio is -29.96 and the forward PE ratio is null. Fulcrum Therapeutics's PEG ratio is 0.34.

    PE Ratio

    n/a
    		 -29.96

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 3.64

    Forward PS

    n/a
    		 5

    PB Ratio

    n/a
    		 1.2

    P/FCF Ratio

    n/a
    		 -116.72

    PEG Ratio

    n/a
    		 0.34
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Fulcrum Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 22.63, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 22.63

    Quick Ratio

    n/a
    		 22.63

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -0.47

    Debt / FCF

    n/a
    		 -3.46

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,777,777.78

    Profits Per Employee

    n/a
    		 $-216,111.11

    Employee Count

    n/a
    		 45

    Asset Turnover

    n/a
    		 0.31

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 17.68% in the last 52 weeks. The beta is 2.42, so Fulcrum Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.42

    52-Week Price Change

    n/a
    		 17.68%

    50-Day Moving Average

    n/a
    		 5.81

    200-Day Moving Average

    n/a
    		 4.22

    Relative Strength Index (RSI)

    n/a
    		 65.97

    Average Volume (20 Days)

    n/a
    		 559,046

    Income Statement

    In the last 12 months, Fulcrum Therapeutics had revenue of 80M and earned -9.72M in profits. Earnings per share was -0.17.

    Revenue

    n/a
    		 80M

    Gross Profit

    n/a
    		 78.41M

    Operating Income

    n/a
    		 -21.9M

    Net Income

    n/a
    		 -9.72M

    EBITDA

    n/a
    		 -18.24M

    EBIT

    n/a
    		 -19.83M

    Earnings Per Share (EPS)

    n/a
    		 -0.17
    Full Income Statement

    Balance Sheet

    The company has 58.21M in cash and 8.63M in debt, giving a net cash position of 49.58M.

    Cash & Cash Equivalents

    n/a
    		 58.21M

    Total Debt

    n/a
    		 8.63M

    Net Cash

    n/a
    		 49.58M

    Retained Earnings

    n/a
    		 -519.4M

    Total Assets

    n/a
    		 242.65M

    Working Capital

    n/a
    		 224.46M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -2.22M and capital expenditures -278K, giving a free cash flow of -2.5M.

    Operating Cash Flow

    n/a
    		 -2.22M

    Capital Expenditures

    n/a
    		 -278K

    Free Cash Flow

    n/a
    		 -2.5M

    FCF Per Share

    n/a
    		 -0.04
    Full Cash Flow Statement

    Margins

    Gross margin is 98.01%, with operating and profit margins of -27.37% and -12.16%.

    Gross Margin

    n/a
    		 98.01%

    Operating Margin

    n/a
    		 -27.37%

    Pretax Margin

    n/a
    		 -12.16%

    Profit Margin

    n/a
    		 -12.16%

    EBITDA Margin

    n/a
    		 -22.8%

    EBIT Margin

    n/a
    		 -27.37%

    FCF Margin

    n/a
    		 -3.12%

    Dividends & Yields

    FULC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for FULC is $4, which is -45.9% lower than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 -45.9%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 14.02

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist